Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 4/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68587 | 0.86 | PRMT5 (0.34) | PRMT5KMT2APIK3CAMTORTNIK | |
| SCHEMBL68028 | 0.86 | ACVR1 (0.42) | ACVR1NOD2RIPK2FYN | |
| SCHEMBL84579 | 0.76 | DGAT1 (0.39) | PIK3CATNIKFYN | |
| SCHEMBL67109 | 0.76 | TNIK (0.43) | PIK3CATNIKFYN | |
| SCHEMBL68131 | 0.67 | PRMT5 (0.40) | PRMT5PIK3CAMTORMAP3K11SUV39H2 | |
| SCHEMBL15181498 | 0.66 | DGAT1 (0.40) | PIK3CAMTOR | |
| SCHEMBL66844 | 0.66 | PRMT5 (0.40) | PRMT5PIK3CAMTORMAP3K11SUV39H2 | |
| SCHEMBL4842921 | 0.65 | HTR2C (0.38) | — | |
| SCHEMBL68603 | 0.62 | TNIK (0.39) | TNIKFYN | |
| SCHEMBL84580 | 0.61 | DGAT1 (0.49) | PIK3CAFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | PRMT5 2251/4885KMT2A 2016/4885PIK3CA 30/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | PRMT5 1689/4885KMT2A 1690/4885PIK3CA 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.